Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$61.27

-2.16 (-3.41%)

, AGN

Allergan

$216.81

-4.44 (-2.01%)

15:32
01/11/17
01/11
15:32
01/11/17
15:32

AbbVie promises to keep drug price increases under 10%, Reuters reports

AbbVie (ABBV) CEO Richard Gonzalez promised to keep all drug price increases in 2017 under 10%, following Allergan (AGN) and Novo Nordisk's (NVO) pledge to do the same, according to Reuters. During the annual JPMorgan Healthcare Conference, the executive said his company would raise prices just once this year, with the percentage increases not exceeding single digits, the publication noted. Reference Link

ABBV

AbbVie

$61.27

-2.16 (-3.41%)

AGN

Allergan

$216.81

-4.44 (-2.01%)

NVO

Novo Nordisk

$35.61

-0.4 (-1.11%)

  • 11

    Jan

  • 27

    Jan

  • 01

    Feb

  • 21

    Feb

ABBV AbbVie
$61.27

-2.16 (-3.41%)

12/19/16
JEFF
12/19/16
DOWNGRADE
Target $48
JEFF
Underperform
Merck downgraded to Underperform from Hold at Jefferies
Jefferies analyst Jeffrey Holford downgraded Merck (MRK) to Underperform, his firm's sell-rating equivalent. The analyst sees Pharmaceutical sector fundamentals weakening in 2017 amid political overhangs and an adverse macro environment. Potential dual eligible rebate reform is the most significant risk, Holford tells investors in a research note. Specific to Merck, the analyst expects further pressure on Keytruda in 2018, driven by share losses in non-small cell lung cancer to Bristol-Myers Squibb (BMY), AstraZeneca (AZN) and Roche (RHHBY). Merck screens poorly on many valuation metrics, Holford contends. He lowered his price target for the shares to $48 from $59. The stock closed Friday up 7c to $62.44. The analyst this morning also upgraded both Bristol-Myers Squibb (BMY) and Bayer (BAYRY) to Buy from Hold. His top picks in Pharmaceuticals are AbbVie (ABBV) and Eli Lilly (LLY) for the U.S. and AstraZeneca and Novartis (NVS) in Europe.
12/21/16
PIPR
12/21/16
NO CHANGE
Target $129
PIPR
Overweight
Vertex well in lead but Galapagos a competitor, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff says that while Galapagos NV (GLPG) and AbbVie's (ABBV) CFTR potentiator GLPG1837 is " clearly a competitor" following the Phase II SAPHIRA-1 data, Vertex Pharmaceuticals (VRTX) remains "well in the lead." The Phase III KALYDECO plus follow-on VX-661 data is expected in the first half of 2017 while the Phase II triple combination data with VX-440 and VX-152 is expected in the second half of the year, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Vertex with a $129 price target.
01/05/17
JEFF
01/05/17
NO CHANGE
Target $90
JEFF
Buy
Jefferies keeps AbbVie as top global Pharma pick for 2017
Jefferies analyst Jeffrey Holford says AbbVie (ABBV) remains his top global pick in Pharmaceuticals for 2017. The stock should again outperform as visibility on the timeline for U.S. Humira biosimilars "increases against bearish consensus expectations," Holford tells investors in a research note. He also expects "important advances" on AbbVie's pipeline throughtout the year, and highlights Rova-T, Imbruvica, Venclexta, risankizumab and veliparib. Holford keeps a Buy rating on the shares with a $90 price target.
11/29/16
MAXM
11/29/16
NO CHANGE
Target $6
MAXM
Sell
Question on Momenta's biosimilar Humira not efficacy, but legality, says Maxim
Maxim analyst Jason McCarthy noted that Momenta (MNTA) announced that M923, its biosimilar version of Humira, met the primary endpoint in a trial of its efficacy, but added that the question about the product "is not efficacy, it is legal." If M923 is approved, a fight over IP with AbbVie (ABBV) could delay the commercial launch to 2022 or later, said McCarthy, who keeps a Sell rating on Momenta shares.
AGN Allergan
$216.81

-4.44 (-2.01%)

01/05/17
WELS
01/05/17
NO CHANGE
WELS
Outperform
Allergan 2017 outlook in-line with estimates, says Wells Fargo
Wells Fargo analyst David Maris says Allergan's preliminary outlook for 2017 today was in-line with his and the current expectations. The analyst notes Allergan's outlook does not include accretion from the recently announced acquisition of LifeCell. Maris keeps an Outperform rating on the shares with a $250-$255 price target range.
12/21/16
BERN
12/21/16
NO CHANGE
BERN
Allergan acquisition has positive aspects, says Bernstein
After Allergan agreed to buy LifeCell, analyst Aaron Gal says that LifeCell seems to "merge well" with Allergan's aesthetics business. The analyst thinks that the acquisition should have "a fair number of synergies," while "LifeCell is another long duration asset that is not protected solely via patent protection." The analyst believes that the cost of the deal is "reasonable." He keeps a $275 price target and an Outperform rating on Allergan.
12/15/16
GSCO
12/15/16
DOWNGRADE
GSCO
Buy
Allergan downgraded to Buy from Conviction Buy at Goldman
12/13/16
EVER
12/13/16
NO CHANGE
Target $296
EVER
Buy
Evercore says Linzess trial an 'under the radar' potential catalyst for Allergan
Evercore ISI analyst Umer Raffat said the readout of the Phase 2b trial of colonic-release Linzess, which is due before year end according to Ironwood (IRWD), is a "wayyy under the radar" potential catalyst for Allergan (AGN), which he notes is partnered on the drug. Expectations are "basically" for the trial to fail completely, but if formulation 1 of colonic release delivers Linzess-like efficacy or has better pain relief than Linzess, it would extend the tail or possibly grow the franchise, he said. In a "blue sky scenario," formulation 2 of colonic release would show good abdominal pain relief, which would open up several new indications for the drug, added Raffat, who has a Buy rating and $296 price target on Allergan shares.
NVO Novo Nordisk
$35.61

-0.4 (-1.11%)

12/06/16
UBSW
12/06/16
UPGRADE
UBSW
Buy
Novo Nordisk upgraded to Buy from Sell at UBS
01/04/17
JPMS
01/04/17
DOWNGRADE
JPMS
Underweight
Novo Nordisk downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Richard Vosser downgraded Novo Nordisk yesterday to Underweight saying consensus expectations are not reflecting the potential for further pricing pressure in the U.S. The analyst has a DKR 225 price target for the shares.
12/15/16
HCWC
12/15/16
NO CHANGE
Target $13
HCWC
Buy
vTv Therapeutics Phase 2 diabetes data a 'big win,' says H.C. Wainwright
H.C. Wainwright analyst Corey Davis views vTv Therapeutics' (VTVT) data from its Phase 2 study of TTP273 in type-2 diabetes as "very positive" and a "big win." Efficacy is close to Novo Nordisk's (NVO) oral semaglutide, Davis tells investors in a research note. vTv is "highly likely" to succeed in finding a partner given the attractiveness of the diabetes market and the differentiated profile '273 has now created, the analyst contends. Davis keeps a Buy rating on the shares with a $13 price target.
01/03/17
JPMS
01/03/17
DOWNGRADE
JPMS
Underweight
Novo Nordisk downgraded to Underweight from Neutral at JPMorgan

TODAY'S FREE FLY STORIES

ICPT

Intercept

$98.12

1.92 (2.00%)

15:41
09/21/17
09/21
15:41
09/21/17
15:41
Recommendations
Intercept analyst commentary  »

Intercept selloff an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$172.17

-0.35 (-0.20%)

15:39
09/21/17
09/21
15:39
09/21/17
15:39
Hot Stocks
Facebook says will help government in ' vitally important ' election probe »

The company said the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

15:38
09/21/17
09/21
15:38
09/21/17
15:38
Hot Stocks
Sanderson Farms up regular dividend to 32c, declares special dividend of $1.00 »

Sanderson Farms announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

15:36
09/21/17
09/21
15:36
09/21/17
15:36
Hot Stocks
Breaking Hot Stocks news story on Sanderson Farms »

Sanderson Farms declares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

15:36
09/21/17
09/21
15:36
09/21/17
15:36
Hot Stocks
Breaking Hot Stocks news story on Sanderson Farms »

Sanderson Farms raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MIK

Michaels

$21.42

-0.03 (-0.14%)

15:30
09/21/17
09/21
15:30
09/21/17
15:30
Options
Bullish flow continues for a third day in Michaels Companies »

Bullish flow continues…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

15:17
09/21/17
09/21
15:17
09/21/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
09/21/17
09/21
15:16
09/21/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:15
09/21/17
09/21
15:15
09/21/17
15:15
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

15:10
09/21/17
09/21
15:10
09/21/17
15:10
General news
Fedspeak is heavy next week, with 12 Committee members scheduled »

Fedspeak is heavy next…

CSX

CSX

$52.81

1.03 (1.99%)

15:05
09/21/17
09/21
15:05
09/21/17
15:05
Hot Stocks
CSX says service 'rapidly' restored following Hurricane Irma »

CSX said that following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 29

    Oct

  • 30

    Oct

GE

General Electric

$24.65

0.33 (1.36%)

15:05
09/21/17
09/21
15:05
09/21/17
15:05
Options
General Electric call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

ICPT

Intercept

$98.12

1.92 (2.00%)

15:00
09/21/17
09/21
15:00
09/21/17
15:00
Downgrade
Intercept rating change  »

Intercept downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$13.70

-0.46 (-3.25%)

14:57
09/21/17
09/21
14:57
09/21/17
14:57
Periodicals
Snap cuts headcount at hardware lab, maker of spectacles, Bloomberg says »

According to the report,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YELP

Yelp

$43.73

-0.44 (-1.00%)

14:55
09/21/17
09/21
14:55
09/21/17
14:55
Options
Yelp put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

14:55
09/21/17
09/21
14:55
09/21/17
14:55
General news
Canada CPI preview »

Canada CPI preview: CPI,…

14:50
09/21/17
09/21
14:50
09/21/17
14:50
General news
Canada retail sales preview »

Canada retail sales…

ICPT

Intercept

$98.12

1.92 (2.00%)

14:49
09/21/17
09/21
14:49
09/21/17
14:49
Recommendations
Intercept analyst commentary  »

Citi calls FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:45
09/21/17
09/21
14:45
09/21/17
14:45
Conference/Events
Cowen retail analyst hold an analyst/industry conference call »

Retailing/Specialty…

PSTG

Pure Storage

$15.32

0.49 (3.30%)

14:45
09/21/17
09/21
14:45
09/21/17
14:45
Options
Pure Storage call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 11

    Dec

NLSN

Nielsen

$40.48

0.06 (0.15%)

, CBS

CBS

$58.90

-0.155 (-0.26%)

14:44
09/21/17
09/21
14:44
09/21/17
14:44
Hot Stocks
CBS to use Nielsen Out-of-Home Reporting Service »

Nielsen (NLSN) announced…

NLSN

Nielsen

$40.48

0.06 (0.15%)

CBS

CBS

$58.90

-0.155 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 28

    Sep

  • 02

    Nov

ALNY

Alnylam

14:41
09/21/17
09/21
14:41
09/21/17
14:41
Hot Stocks
Alnylam CEO 'confident' patisiran is best-in-class treatment »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESRX

Express Scripts

$61.82

0.82 (1.34%)

, NVS

Novartis

$85.01

-0.77 (-0.90%)

14:41
09/21/17
09/21
14:41
09/21/17
14:41
Hot Stocks
Express Scripts CMO discusses 'great promise, big price' of gene therapy »

In a post to the…

ESRX

Express Scripts

$61.82

0.82 (1.34%)

NVS

Novartis

$85.01

-0.77 (-0.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 22

    Sep

  • 25

    Oct

  • 08

    Nov

  • 17

    May

ALNY

Alnylam

$113.84

38.8 (51.71%)

14:40
09/21/17
09/21
14:40
09/21/17
14:40
Hot Stocks
Alnylam CEO says more confident in other trials after patisiran data »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTX

Minerals Technologies

$69.50

1.1 (1.61%)

14:33
09/21/17
09/21
14:33
09/21/17
14:33
Hot Stocks
Minerals Technologies authorizes $150M, two-year share repurchase program »

Minerals Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.